Impact of Prior Immune Checkpoint Inhibitor Treatment on the Efficacy of Weekly Paclitaxel and Cetuximab in Recurrent or Metastatic Head and Neck Cancer.

IF 2.1 4区医学 Q4 ONCOLOGY

Asia-Pacific journal of clinical oncology Pub Date : 2026-08-24 DOI:10.1111/ajco.70163

Shohei Tsutsumi, Shunsuke Miyamoto, Kaho Momiyama, Kohei Hagiwara, Taku Yamashita

{"title":"Impact of Prior Immune Checkpoint Inhibitor Treatment on the Efficacy of Weekly Paclitaxel and Cetuximab in Recurrent or Metastatic Head and Neck Cancer.","authors":"Shohei Tsutsumi, Shunsuke Miyamoto, Kaho Momiyama, Kohei Hagiwara, Taku Yamashita","doi":"10.1111/ajco.70163","DOIUrl":null,"url":null,"abstract":"Aim: The optimal treatment sequence involving immune checkpoint inhibitors (ICIs) and chemotherapy for recurrent or metastatic head and neck cancer remains unclear. This study aimed to evaluate the efficacy of weekly paclitaxel and cetuximab (PTX + Cmab) following prior ICI treatment.Methods: We retrospectively analyzed 52 patients with unresectable recurrent or metastatic head and neck cancer who received PTX + Cmab. Patients were divided into two groups according to prior ICI treatment status. Treatment outcomes, including overall response rate (ORR), progression-free survival (PFS), and overall survival (OS), were compared.Results: The ORR was 42.2%. Patients with prior ICI treatment showed a significantly higher ORR compared to those without prior ICI treatment (61.5% vs. 15.8%, p = 0.003). PFS was significantly longer in patients with prior ICI treatment (median, 5.4 vs. 4.4 months, p = 0.04). OS did not differ significantly between the groups (median, 15.1 vs. 11.0 months).Conclusion: PTX + Cmab was associated with a higher response rate and longer PFS in patients with prior ICI treatment. These findings suggest a clinical association between prior ICI treatment and improved response to subsequent PTX + Cmab.","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajco.70163","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: The optimal treatment sequence involving immune checkpoint inhibitors (ICIs) and chemotherapy for recurrent or metastatic head and neck cancer remains unclear. This study aimed to evaluate the efficacy of weekly paclitaxel and cetuximab (PTX + Cmab) following prior ICI treatment.

Methods: We retrospectively analyzed 52 patients with unresectable recurrent or metastatic head and neck cancer who received PTX + Cmab. Patients were divided into two groups according to prior ICI treatment status. Treatment outcomes, including overall response rate (ORR), progression-free survival (PFS), and overall survival (OS), were compared.

Results: The ORR was 42.2%. Patients with prior ICI treatment showed a significantly higher ORR compared to those without prior ICI treatment (61.5% vs. 15.8%, p = 0.003). PFS was significantly longer in patients with prior ICI treatment (median, 5.4 vs. 4.4 months, p = 0.04). OS did not differ significantly between the groups (median, 15.1 vs. 11.0 months).

Conclusion: PTX + Cmab was associated with a higher response rate and longer PFS in patients with prior ICI treatment. These findings suggest a clinical association between prior ICI treatment and improved response to subsequent PTX + Cmab.

查看原文本刊更多论文

既往免疫检查点抑制剂治疗对每周紫杉醇和西妥昔单抗治疗复发或转移性头颈癌疗效的影响

目的：免疫检查点抑制剂（ICIs）和化疗对复发或转移性头颈癌的最佳治疗顺序尚不清楚。本研究旨在评估既往ICI治疗后每周紫杉醇和西妥昔单抗（PTX + Cmab）的疗效。方法：回顾性分析52例接受PTX + Cmab治疗的不可切除的复发或转移性头颈癌患者。根据患者既往ICI治疗情况分为两组。比较治疗结果，包括总缓解率（ORR）、无进展生存期（PFS）和总生存期（OS）。结果：总有效率为42.2%。与未接受ICI治疗的患者相比，有ICI治疗史的患者ORR明显更高（61.5%比15.8%,p = 0.003）。先前接受过ICI治疗的患者PFS明显更长（中位数，5.4个月对4.4个月，p = 0.04）。两组间OS无显著差异（中位数，15.1个月vs. 11.0个月）。结论：PTX + Cmab与既往ICI治疗患者更高的缓解率和更长的PFS相关。这些发现表明，先前的ICI治疗与随后PTX + Cmab的改善应答之间存在临床关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asia-Pacific journal of clinical oncology 医学-肿瘤学

CiteScore

3.40

自引率

0.00%

发文量

175

审稿时长

6-12 weeks

期刊介绍： Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.